Literature DB >> 11352850

Insulin-like growth factors and prostate cancer: a population-based case-control study in China.

A P Chokkalingam1, M Pollak, C M Fillmore, Y T Gao, F Z Stanczyk, J Deng, I A Sesterhenn, F K Mostofi, T R Fears, M P Madigan, R G Ziegler, J F Fraumeni, A W Hsing.   

Abstract

Insulin-like growth factors (IGFs) have potent mitogenic and antiapoptotic effects on prostate epithelial cells. Through modulation of IGF bioactivity and other mechanisms, IGF-binding proteins (IGFBPs) also have growth-regulatory effects on prostate cells. Recently, IGF-I and IGFBP-3 have been implicated in prostate cancer risk among Western populations. To assess whether IGF-I, IGF-II, IGFBP-1, or IGFBP-3 are also associated with prostate cancer in a low-risk population, we measured plasma levels of these factors among 128 newly diagnosed prostate cancer cases and 306 randomly selected population controls in Shanghai, China. Relative to the lowest quartile of IGF-I levels, men in the highest quartile had a 2.6-fold higher prostate cancer risk, with a significant trend [odds ratio (OR) = 2.63; 95% confidence interval (95% CI) = 1.19-5.79; P(trend) = 0.01]. In contrast, men in the highest quartile of IGFBP-3 levels had a 46% decreased risk relative to the lowest quartile (OR = 0.54; 95% CI = 0.26-1.15; P(trend) = 0.08). A similar but less distinct result was observed for IGFBP-1 (OR = 0.60; 95% CI = 0.31-1.17; P(trend) = 0.25). Men in the highest quartile for the IGF-I:IGFBP-3 molar ratio (an indirect measure of free IGF-I) had a 2.5-fold higher risk compared with the lowest quartile (OR = 2.51; 95% CI = 1.32-4.75, P(trend) < 0.001). These associations were more pronounced after adjustment for serum 5alpha-androstane-3alpha,17beta-diol glucuronide and sex hormone-binding globulin levels. There was no significant association with IGF-II levels. Our findings in a low-risk population provide evidence that IGF-I, IGFBP-3, and IGFBP-1 are determinants of prostate cancer and indicate that additional studies are needed to evaluate their effects on ethnic and geographic incidence differentials and to elucidate carcinogenic mechanisms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11352850

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  24 in total

1.  Effects of a 12-week home-based exercise program on the level of physical activity, insulin, and cytokines in colorectal cancer survivors: a pilot study.

Authors:  Dong Hoon Lee; Ji Young Kim; Mi Kyung Lee; Choae Lee; Ji-Hee Min; Duck Hyoun Jeong; Ji-Won Lee; Sang Hui Chu; Jeffrey A Meyerhardt; Jennifer Ligibel; Lee W Jones; Nam Kyu Kim; Justin Y Jeon
Journal:  Support Care Cancer       Date:  2013-05-02       Impact factor: 3.603

Review 2.  Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy.

Authors:  Jennifer Wu; Evan Yu
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

3.  Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer.

Authors:  Yin Cao; Katharina Nimptsch; Irene M Shui; Elizabeth A Platz; Kana Wu; Michael N Pollak; Stacey A Kenfield; Meir J Stampfer; Edward L Giovannucci
Journal:  Int J Cancer       Date:  2014-11-10       Impact factor: 7.396

4.  Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT.

Authors:  Mari-Anne Rowlands; Jeff M P Holly; David Gunnell; Jenny Donovan; J Athene Lane; Freddie Hamdy; David E Neal; Steven Oliver; George Davey Smith; Richard M Martin
Journal:  Cancer Res       Date:  2011-11-21       Impact factor: 12.701

Review 5.  Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis.

Authors:  Mari-Anne Rowlands; David Gunnell; Ross Harris; Lars J Vatten; Jeff M P Holly; Richard M Martin
Journal:  Int J Cancer       Date:  2009-05-15       Impact factor: 7.396

6.  Hypertension, obesity and prostate cancer biochemical recurrence after radical prostatectomy.

Authors:  R Asmar; J L Beebe-Dimmer; K Korgavkar; G R Keele; K A Cooney
Journal:  Prostate Cancer Prostatic Dis       Date:  2012-08-21       Impact factor: 5.554

7.  Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/paracrine factors.

Authors:  Feng Sun; He-ge Chen; Wei Li; Xi Yang; Xin Wang; Richeng Jiang; Zhiyong Guo; Hegang Chen; Jiaoti Huang; Alexander D Borowsky; Yun Qiu
Journal:  J Biol Chem       Date:  2013-12-02       Impact factor: 5.157

8.  Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies.

Authors:  Wensen Chen; Sumin Wang; Tian Tian; Jianling Bai; Zhibin Hu; Yan Xu; Jing Dong; Feng Chen; Xinru Wang; Hongbing Shen
Journal:  Eur J Hum Genet       Date:  2009-06-03       Impact factor: 4.246

Review 9.  Considering GH replacement for GH-deficient adults with a previous history of cancer: a conundrum for the clinician.

Authors:  Kevin C J Yuen; Anthony P Heaney; Vera Popovic
Journal:  Endocrine       Date:  2016-01-05       Impact factor: 3.633

10.  A list of candidate cancer biomarkers for targeted proteomics.

Authors:  Malu Polanski; N Leigh Anderson
Journal:  Biomark Insights       Date:  2007-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.